More than 1,000 eye care professionals worldwide have been using the AdaptDx® and AdaptDx Pro® to test for impaired dark adaptation, the earliest biomarker of age-related macular degeneration. Our customers tell the story of how they’re fighting against preventable blindness by identifying AMD at its earliest stages and closely monitoring its progression.
When I look at the future of managing macular degeneration, I see the AdaptDx as the essential tool in AMD management just as now I see the OCT as the essential tool in managing glaucoma in its earliest stages. By finding a disease early, and intervening appropriately we have the best chance of altering the course.
I have advanced AMD and I wish the AdaptDx Pro had been available for me years ago. Maybe I wouldn’t be here today. I wouldn’t want anyone to go through this if there’s a way to prevent it or treat it early and give people a better quality of life for longer period of time. I encourage everybody. Take advantage of this technology. It’s wonderful.
The AdaptDx Pro gives us the opportunity to change the future of macular degeneration care because it allows us to screen everyone at risk and identify macular degeneration earlier. The whole objective is to reduce the number of patients losing vision from macular degeneration.
The AdaptDx was painless and easy to follow. I had to push a clicker when I would see a certain light. They told me it was a little lengthy but it didn’t seem that long.
The AdaptDx Pro has allowed me to bring automated dark adaptation testing to any and every location in my practice. The patient experience is excellent and the data obtained is actionable. I'm proud that my practice will continue to do everything we can to reduce the risk of blindness caused by AMD.
Macular degeneration is 3 times more prevalent than glaucoma and diabetic retinopathy combined. So why would I not use the AdaptDx test on everybody over the age of 50? Oh, and did I mention it helps you identify signs of subclinical AMD before you can see drusen or mottling in the eye itself?
Just like the OCT, I don't know how I practiced without the AdaptDx. Being able to diagnose AMD before we see any clinical signs and being able to monitor at the correct follow-up time for my patients that have AMD is wonderful. I felt like it was just a shot in the dark as to when I should have early AMD patients return, but now knowing their rod intercept, I can confidently say exactly when their follow-ups should be.
Prior to having the AdaptDx, I struggled with patients having complaints of night vision issues. Providing a recheck of their refractive findings and another look at their retina always came up negative. I knew this patient was providing me a legitimate complaint, but I could provide no clinical basis for this complaint. Now we test these patients using the AdaptDx and in minutes discover if their complaint is consistent with subclinical AMD. This allows me to not only diagnose their complaint, but the patient is also able to start treatment even earlier with supplementation and making lifestyle changes.
After five years of using the AdaptDx to help identify AMD at its earliest stage and then placing patients on a treatment regimen involving modifiable risk factors, I have documented many patients having improved Rod Intercept times (improved dark adaptation) and maintaining their visual acuity.
The first AMD symptom I noticed was problems reading in a dim room. When the light was bright, I had no issues. But when the light was dimmed, I just could not make out that small print.